Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Nektar TherapeuticsNASDAQ: NKTR

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares growth accelerates

Q2 FY2026 weighted avg shares of 33.05M shares rose 134.6% year over year, ahead of the +64.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 33.6% from the prior quarter. Over 3 fiscal years it compounded at +10.6% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +134.6% holds above the trailing-twelve-month pace of +64.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
33.05M+33.6% QoQ
Last fiscal yearDec 2025
16.87M+23.0% YoY
LTMJun 2026
23.04M+64.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+134.6%——
1 year+23.0%——
3-year CAGR+10.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
16.87M USD
Year-over-year change
+23.0%
4-year CAGR
+8.4%

Weighted Avg Shares vs competitors

How NKTR compares with its peers on the latest reported figures

  • NKTR's LTM Jun 2026 weighted avg shares of 23.04M shares is the 10th highest of the 11 companies compared; the peer median is 85.9M shares.
  • Its year-over-year change of +64.4% is the highest of 10, against a peer median of +6.0%.
  • Over three fiscal years its annual growth of +10.6% compares with a peer median of +7.7%.
NKTR Competitors Peer median
Weighted Avg Shares for NKTR and competitors
Company Period LTM YoY 3-year CAGR
IMTXImmatics N.V.LTM Mar 2026125.95M +14.7%+22.1%
CHRSCoherus Oncology, Inc.LTM Mar 2026122.27M +6.0%+15.7%
RCUSArcus Biosciences, Inc.LTM Jun 2026116.35M +20.1%+14.3%
CGENCompugen Ltd.LTM Mar 202693.98M +4.2%+2.6%
IPHAInnate Pharma S.A.FY202589.42M +10.3%+4.0%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 202682.39M +23.5%+19.3%
XNCRXencor, Inc.LTM Jun 202674.94M +5.1%+7.6%
MGNXMacroGenics, Inc.LTM Mar 202663.24M +0.8%+0.9%
IMCRImmunocore Holdings plcLTM Mar 202650.45M +0.8%+3.3%
NKTRNektar TherapeuticsLTM Jun 202623.04M +64.4%+10.6%
ANLAdlai Nortye Ltd.LTM Jun 20247.76M —+7.9%
Peer median (excluding NKTR) 85.9M+6.0%+7.7%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue101.91M92.06M90.12M98.43M55.23M
Cost of Revenue24.9M21.64M36.64M30.69M0
Gross Profit77.01M70.42M53.48M67.74M55.23M
Gross Margin75.6%76.5%59.3%68.8%100.0%
Research & Development400.27M218.32M114.16M120.91M117.33M
Selling, General & Admin122.84M92.33M77.42M76.75M68.67M
Operating Expenses523.11M310.66M190.9M172.94M186M
Depreciation & Amortization14.15M12.2M7.82M4.39M1.03M
EBITDA(461.82M)(323.87M)(243.11M)(86.7M)(137M)
EBITDA Margin-453.2%-351.8%-269.8%-88.1%-248.1%
Operating Income(446.1M)(240.24M)(137.43M)(105.2M)(130.77M)
Operating Margin-437.8%-261.0%-152.5%-106.9%-236.8%
Interest Income2.73M6.78M19.01M14.5M10.44M
Interest Expense47.31M28.91M25.33M28.11M26.18M
Other Income / Expenses(77.18M)(124.75M)(138.83M)(14M)(33.44M)
Income Before Tax(523.28M)(364.98M)(276.26M)(119.2M)(164.21M)
Pre-Tax Margin-513.5%-396.5%-306.5%-121.1%-297.3%
Income Tax Expense557K3.22M(200K)(239K)(138K)
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Net Margin-514.0%-400.0%-306.3%-120.9%-297.1%
EPS (Basic)(42.90)(29.51)(21.79)(8.68)(9.73)
EPS (Diluted)(42.90)(29.51)(21.79)(8.68)(9.73)
Weighted Avg Shares12.22M12.48M12.67M13.71M16.87M
Weighted Avg Shares (Diluted)12.22M12.48M12.67M13.71M16.87M

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.